ProCE Banner Activity

Overview, Rationale, and Guidance on Testing for Rare Genomic Fusions in NSCLC

Slideset Download

Download these slides from a live symposium at ASCP 2022 featuring guidance from a pathologist on best practices for detection of gene fusions in advanced non-small-cell lung cancer along with the latest clinical evidence on targeted therapies available for the treatment of RET and NTRK fusion–positive disease.

Released: September 14, 2022

Share

Faculty

Jeremy P. Segal

Jeremy P. Segal, MD, PhD

Associate Professor
Department of Pathology
Director
Molecular and Cytogenetic Pathology
University of Chicago
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc, Blueprint Medicines and Genentech, a member of the Roche Group, and Lilly.

Bayer HealthCare Pharmaceuticals Inc.

Blueprint Medicines and Genentech, a member of the Roche Group

Lilly

Partners

American Society for Clinical Pathology

ProCE Banner

Partnered with the American Society for Clinical Pathology.

Faculty Disclosure

Primary Author

Jeremy P. Segal, MD, PhD

Associate Professor
Department of Pathology
Director
Molecular and Cytogenetic Pathology
University of Chicago
Chicago, Illinois

Jeremy P. Segal, MD, PhD: consultant/advisor/speaker: AstraZeneca, Bayer, Lilly.